Results 121 to 130 of about 26,268,555 (308)

National Treatment Purchase Fund annual report 2004.

, 2004
The mission of the National Treatment Purchase Fund is to reduce the length of time public patients are on hospital waiting lists by offering them a choice in obtaining access to treatment quickly, safely and to a high standard of patient satisfaction ...
National Treatment Purchase Fund
core  

First-line therapies in inflammatory bowel disease [PDF]

, 2012
BACKGROUND AND AIMS: Medical therapy of inflammatory bowel disease (IBD) is becoming more complex, given the increasing choice of drugs to treat Crohn's disease (CD) and ulcerative colitis (UC). We aimed to summarize the current guidelines for first-line
Safroneeva, Ekaterina, Rogler, Gerhard, Alain M. Schoepfer, Manz, Michael, Mottet, Christian, Roger Wanner, Ekaterina Safroneeva, Gerhard Rogler, Pascal Frei, Frei, Pascal, Luc Biedermann, Michael Manz, Christian Mottet, Christine Manser, Girardin, Marc, Manser, Christine, Wanner, Roger, Marc Girardin, Biedermann, Luc, Schoepfer, Alain M, Safroneeva, E., Manz, M., Manser, C., Manz M, Girardin, M., Biedermann L, Mottet C, Rogler, G., Rogler G, Schoepfer AM, Girardin M, Mottet, C., Wanner, R., Biedermann, L., Safroneeva E, Frei P, Frei, P., Schoepfer, A.M., Manser C, Wanner R   +39 more
core   +2 more sources

Structural and biochemical analysis of a B12 superbinder

FEBS Letters, EarlyView.
BtuG proteins are vitamin B12 scavengers in Bacteroides thetaiotaomicron, a dominant human gut bacterium. We present crystal structures of three BtuG homologs bound to cobalamin and its precursor cobinamide, revealing picomolar binding affinities, among the highest known for any natural protein.
Jose M. Martinez Felices, Jacob J. Whittaker, Dirk J. Slotboom, Albert Guskov   +3 more
wiley   +1 more source

From junk to function — How weak selection in eukaryotes builds new parts and drives genomic complexity

FEBS Letters, EarlyView.
How do genomes gain new functional parts? In eukaryotes, which tend to evolve under weak selection, much of the genome is junk. Palazzo and Qiu borrow the logic of Markov chains to show how non‐functional DNA becomes functional through the appearance of intermediate states, which arise due to epistasis, buffering, and biochemical messiness, allowing ...
Alexander F. Palazzo, Yi Qiu
wiley   +1 more source

First line treatment in hypertension.

BMJ, 1991
L E Ramsay, W W Yeo
  +7 more sources

L‐aspartate oxidase provides new insights into fumarate reduction in anaerobic darkness in Synechocystis sp. PCC6803

FEBS Letters, EarlyView.
Synechocystis strains deficient in succinate dehydrogenase (SDH) secrete more succinate than the WT under dark anaerobic conditions, supporting that SDH then primarily acts as SDH, not as a fumarate reductase. L‐aspartate oxidase (Laspo) from Synechocystis is functional under anaerobic conditions, reducing fumarate to succinate.
Kateryna Kukil, Jeffrey A. Hawkes, Cecilia Blikstad, Pia Lindberg   +3 more
wiley   +1 more source

Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers

Biologics: Targets & Therapy, 2021
Mimma Rizzo,1 Patrizia Giannatempo,2 Camillo Porta1,3 1Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; 2Department of Medical Oncology, Fondazione I.R.C.C.S.
Rizzo M, Giannatempo P, Porta C
doaj  

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma

, 2013
Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma.
Utkarsh Painuly, Shaji Kumar
core   +1 more source

The heterodimeric amino acid transporters (HAT) of the SLC7/SLC3 family: A structure−function relationships and relevance to human pathology

FEBS Letters, EarlyView.
Heterodimeric amino acid transporters consist of SLC7 and SLC3 family proteins arranged in a conserved structural organization. They regulate nutrient transport across cell membranes, supporting essential cellular functions. These transporters also contribute to xenobiotic/drug uptake and distribution.
Mariafrancesca Scalise, Tiziano Mazza, Raffaella Scanga, Lara Console, Michele Galluccio, Cesare Indiveri   +5 more
wiley   +1 more source

Newly diagnosed ovarian cancer: Which first-line treatment?

, 2020
Poly ADP -Ribose Polymerase (PARP) inhibitors (PARPi) were firstly licensed for maintenance treatment in recurrent, platinum-sensitive, platinum responsive epithelial ovarian cancer patients, harboring or not a BRCA mutation. Three new phase III trials –
Scambia G., Muratore M., Lorusso D., Salutari V., Nero C., Domenica Lorusso, Francesca Ciccarone, Camilla Nero, Gennaro Daniele, Antonella Pietragalla, Giovanni Scambia, Margherita Muratore, Valentina Ceni, Vanda Salutari   +13 more
core   +1 more source